EBOS Group (ASX:EBO) Gains 0.74% — Healthcare Distribution Growth Keeps It on Investors' Radar

Sonal Goyal

04 September 2026 05:33 PM AEST

EBOS Group (ASX:EBO) Gains 0.74% — Healthcare Distribution Growth Keeps It on Investors' Radar

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

• EBOS Group rose 0.74% to $16.955 on 4 September 2026

• HY2026 Revenue growth of 13.0% for the six months ended 31 December 2025

• Underlying EBITDA increased 3.2% to A$300 million in HY2026

• FY2026 EBITDA guidance reaffirmed and distribution-centre renewal program continued

EBOS Group Ltd (ASX:EBO) edged higher by 0.74% to $16.955 on 4 September 2026. The trans-Tasman healthcare and animal care distributor has delivered steady half-year results, reaffirmed annual guidance, and continued investing in its infrastructure — factors that are keeping the stock in favour with defensive-minded investors.

About the Company

EBOS Group is one of Australasia's largest and most diversified healthcare companies, with operations spanning pharmaceutical distribution, healthcare logistics, retail pharmacy ownership and animal care products. Headquartered in Christchurch, New Zealand, EBOS distributes prescription and over-the-counter medicines, medical devices and consumables across Australia and New Zealand. Its animal care division is one of the market leaders in veterinary and agricultural products in the region.

Key Developments

EBOS Group reported HY2026 revenue growth of 13.0% for the six months ended 31 December 2025. Underlying EBITDA increased 3.2% to A$300 million, while Healthcare EBITDA rose 1.3% to A$254 million and Animal Care EBITDA increased 15.1% to A$68 million. The company reaffirmed FY2026 EBITDA guidance and continued its distribution-centre renewal program.

Key Catalysts to Watch

• Full-year FY2026 results and any updated FY2027 guidance

• Completion of distribution-centre renewal program improving operational efficiency

• Growth in the animal care segment, which delivered 15.1% EBITDA growth

• Potential acquisitions in healthcare distribution or animal care markets

Risks

• Healthcare EBITDA growing at just 1.3% in HY2026 — slower than headline revenue

• Competitive pressure in pharmaceutical distribution

• Integration risks from any new acquisitions

• Currency exposure given New Zealand-based earnings

Conclusion

EBOS Group continues to be a steady compounder in the healthcare distribution space. The 13% revenue growth and reaffirmed EBITDA guidance provide a reliable foundation, while the strong animal care division adds a Diversification angle. The 0.74% gain on 4 September is consistent with the stock's low-volatility, dividend-paying character. Investors seeking defensive healthcare exposure with reliable Earnings may find EBOS worth keeping on their watchlist.

FAQs

Q:Why did EBOS Group rise on 4 September 2026?

A:EBO gained 0.74% to $16.955, reflecting positive sentiment around its solid HY2026 results and reaffirmed full-year EBITDA guidance.

Q:What was EBOS Group's revenue growth in HY2026?

A:EBOS Group reported revenue growth of 13.0% in the six months ended 31 December 2025.

Q:How did the animal care division perform?

A:EBOS's animal care EBITDA increased 15.1% to A$68 million in HY2026, outpacing the healthcare segment.

Q:What is EBOS Group's main business?

A:EBOS is one of Australasia's largest healthcare and animal care distributors, with pharmaceutical distribution, retail pharmacy and veterinary product operations across Australia and New Zealand.

Q:What are the risks for EBOS investors?

A:Risks include slower healthcare EBITDA growth, competition in distribution, acquisition integration risk, and currency exposure from New Zealand operations.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.